

**CSL Limited** 

ABN: 99 051 588 348 655 Elizabeth Street Melbourne Victoria 3000 Australia T +613 9389 1911 F +613 9389 1434

## ASX Announcement

For immediate release

5 November 2024

#### APPENDIX 3Y - CHANGE IN DIRECTOR'S INTEREST

The attached Appendix 3Y relates to changes in the relevant interest in the Company's securities held by the Chief Executive Officer (CEO) of CSL Limited, Dr Paul McKenzie.

A grant of Performance Share Units has been made to Dr McKenzie following approval from shareholders at CSL's Annual General Meeting held on 29 October 2024.

Following approval through CSL's governance processes, Dr McKenzie has also sold shares from Long-Term Incentive (LTI) awards that have vested from grants made under CSL's remuneration plan.

The sale was made to meet taxation obligations and for portfolio diversification purposes.

Following these transactions, Dr McKenzie continues to hold a significant interest in the Company's securities, comprising 22,952 ordinary shares. This represents a shareholding of approximately 230% of his base salary.

Dr McKenzie remains on track to achieve CSL's minimum guideline for its Chief Executive Officer which is to hold shares worth three times base salary within five years of appointment - a reflection of the Company's remuneration model that links executive pay to the continued achievement of CSL's long-term strategy.

Authorised for lodgment by:

Fiona Mead

**Company Secretary** 

#### For further information, please contact:

Investors:

Chris Cooper Head, Investor Relations CSL Limited P: +61 455 022 740 Bernard Ronchi Director, Investor Relations CSL Limited P: +61 3 9389 3470 Stephen McKeon
Director, Investor Relations
CSL Limited
P: 61 402 231 696

Media: Jimmy Baker Communications CSL Limited P: +61 450 909 211

 $\hbox{E: chris.cooper@csl.com.au E: bernard.ronchi@csl.com.au E: stephen.mckeon@csl.com.au E: jimmy.baker@csl.com.au E: jimm$ 

Rule 3.19A.2

# **Appendix 3Y**

## **Change of Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	CSL Limited
ABN	99 051 588 348

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Paul McKenzie
Date of last notice	5 September 2024

#### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect interest
Nature of indirect interest	Solium Nominees (Australia) Pty Ltd as custodian
(including registered holder)	for the CSL Limited Performance Rights Plan (the
Note: Provide details of the circumstances giving rise to the relevant interest.	Plan)
Date of change	30 October 2024 and 31 October 2024
No. of securities held prior to change	Direct:
	Nil.
	Indirect:
	65,457 Performance Share Units held by
	Solium Nominees (Australia) Pty Ltd as custodian for the CSL Limited Performance Rights Plan (the Plan).
	26,952 Ordinary Shares held by
	Solium Nominees (Australia) Pty Ltd as custodian for the CSL Limited Performance Rights Plan (the Plan).

<sup>+</sup> See chapter 19 for defined terms.

Class	<ul> <li>Ordinary Shares</li> <li>Performance Share Units under the CSL Limited Performance Rights Plan (the <i>Plan</i>). Subject to satisfaction of certain performance hurdles and the other rules of the Plan, each Performance Share Unit carries the right to subscribe for or acquire one ordinary share in CSL Limited.</li> </ul>
Number acquired	38,065 Performance Share Units (30 October 2024)
Number disposed	4,000 Ordinary Shares (31 October 2024)
Value/Consideration  Note: If consideration is non-cash, provide details and estimated valuation	No consideration was paid or received for the grant of Performance Share Units.
	Consideration received from the sale of 4,000 Ordinary Shares was \$1,148,600.00 (being 4,000 Ordinary Shares at a price of \$287.15).
No. of securities held after change	Direct: Nil.
	Indirect: 103,522 Performance Share Units held by Solium Nominees (Australia) Pty Ltd as custodian for the CSL Limited Performance Rights Plan (the Plan).
	22,952 Ordinary Shares held by Solium Nominees (Australia) Pty Ltd as custodian for the CSL Limited Performance Rights Plan (the Plan).
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Grant of Performance Share Units pursuant to the Plan as a long term incentive for Dr McKenzie as approved by shareholders at the 2024 Annual General Meeting.
	4,000 Ordinary Shares – On market trade for taxation obligations and portfolio diversification.

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	No
Nature of interest	

Appendix 3Y Page 2 01/01/2011

<sup>+</sup> See chapter 19 for defined terms.

Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change  Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

## Part 3 – \*Closed period

Were the interests in the securities or contracts detailed above traded during a *closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

Fiona Mead Company Secretary

5 November 2024

<sup>+</sup> See chapter 19 for defined terms.